Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Features

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Closely-held Lobo Genetics is taking its cannabis genetic profile testing to the next level. “We started with genetic tests and genetic profiling and now we are complementing that by helping guide consumers to the right...

November 5, 2019

Features

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

October 29, 2019

Features

Salarius Pharmaceuticals targeting epigenetic causes of cancers

David Arthur, President and CEO Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the...

October 22, 2019

Features

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Features

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Daniel O’Connor, President and CEO OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse...

October 8, 2019

Features

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

Sebastian Hadjiantoniou As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the...

October 1, 2019

Features

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

Dr. RJ Tesi, CEO and CMO INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead...

September 24, 2019

Spring Bank heading into data-rich 2020

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Soricimed’s platform of unique peptides making waves in cancer and beyond

Salarius Pharmaceuticals targeting epigenetic causes of cancers

KemPharm sees license deal, debt restructuring as transformative events

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

Follow Us

Subscribe

General

More

Subscribe